AFAP1L2
- Known as:
- AFAP1L2
- Catalog number:
- 001263A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- AFAP1L2
Related genes to: AFAP1L2
- Gene:
- AFAP1L2 NIH gene
- Name:
- actin filament associated protein 1 like 2
- Previous symbol:
- KIAA1914
- Synonyms:
- FLJ14564, Em:AC005383.4, XB130
- Chromosome:
- 10q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 2004-02-18
- Date modifiied:
- 2016-10-05
Related products to: AFAP1L2
Related articles to: AFAP1L2
- Disturbances in the endometrial immune microenvironment, particularly uterine natural killer (uNK) cell polarization, are linked to chronic endometritis (CE) and recurrent implantation failure (RIF). However, the underlying mechanisms and a lack of reliable biomarkers hinder effective clinical diagnosis and treatment. - Source: PubMed
Publication date: 2025/11/07
Xie QiuyinZhang LuYang JingYang MengjieLi QiyuanChen Qionghua - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), and SARS-CoV-2 has been linked to changes in DNA methylation (DNAm) patterns. Studies focused on post-SARS-CoV-2 infection and DNAm have been mainly carried out among severe COVID-19 cases or without distinguishing the severity of cases. However, investigations into mild and asymptomatic cases after SARS-CoV-2 infection are limited. In this study, we analyzed DNAm patterns of mild and asymptomatic cases seven months after SARS-CoV-2 infection in a household setting by conducting epigenome-wide association studies (EWAS). - Source: PubMed
Publication date: 2025/04/18
Hong PeizhenWaldenberger MelaniePritsch MichaelGilberg LeonardBrand IsabelBruger JanFrese JonathanCastelletti NoemiGarí MercèGeldmacher ChristofHoelscher MichaelPeters AnnetteMatías-García Pamela R - Sorafenib is the most widely used first-line drug for the treatment of the advanced hepatocellular carcinoma (HCC). Unfortunately, sorafenib resistance often limits its therapeutic efficacy. To evaluate the efficacy of artesunate against sorafenib-resistant HCC and to investigate its underlying pharmacological mechanisms, a "sorafenib resistance related gene-ART candidate target" interaction network was constructed, and a signaling axis consisting with artesunate candidate target AFAP1L2 and sorafenib target SRC, and the downstream FUNDC1-dependent mitophagy was identified as a major contributor to the sorafenib resistance and a potential way of artesunate to mitigate resistance. Notably, our clinical data demonstrated that AFAP1L2 expression in HCC tissues was markedly higher than that in adjacent non-cancerous liver tissues ( < 0.05), and high AFAP1L2 expression was also significantly associated with an unfavorable overall survival of HCC patients ( < 0.05). Experimentally, AFAP1L2 was overexpressed in sorafenib resistant cells, leading to the activation of downstream SRC-FUNDC1 signaling axis, further blocking the FUNDC1 recruitment of LC3B to mitochondria and inhibiting the activation of mitophagy, based on both in vitro and in vivo systems. Moreover, artesunate significantly enhanced the inhibitory effects of sorafenib on resistant cells and tumors by inducing excessive mitophagy. Mechanically, artesunate reduced the expression of AFAP1L2 protein, suppressed the phosphorylation levels of SRC and FUNDC1 proteins, promoted the FUNDC1 recruitment of massive LC3B to mitochondria, and further overactivated the mitophagy and subsequent cell apoptosis of sorafenib resistant cells. In conclusion, artesunate may be a promising strategy to mitigate sorafenib resistance in HCC via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy. AFAP1L2, actin filament associated protein 1 like 2; ANOVA, analysis of variance; ANXA5, annexin V; ART: artesunate; CETSA, cellular thermal shift assay; CI: combination index; CO-IP: co-immunoprecipitation; CQ: chloroquine; CT, computed tomography; [F]-FDG, fluoro-2-D-deoxyglucose F18; FUNDC1: FUN14 domain containing 1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HCC, hepatocellular carcinoma; H&E Staining: hematoxylin - eosin staining; HepG2, sorafenib resistant HepG2; IF, immunofluorescence; IHC, immunohistochemistry; LAMP1: lysosomal associated membrane protein 1; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; miR, microRNA; mRNA: messenger RNA; OE, overexpression; OS, overall survival; PET, positron emission tomography; qRT-PCR: quantitative real-time PCR; sh, short hairpin; shNC: negative control shRNA; sh: short hairpin ; SORA, sorafenib; SPR, surface plasmon resonance; SRC, SRC proto-oncogene, non-receptor tyrosine kinase; SUV, standardized uptake value; TEM, transmission electron microscopy; TOMM20: translocase of outer mitochondrial membrane 20. - Source: PubMed
Publication date: 2023/10/05
Ma ZhaochenChen WenjiaLiu YudongYu LingxiangMao XiaGuo XiaodongJiang FunengGuo QiuyanLin NaZhang Yanqiong - The aim of this study was to assess the prognostic value of XB130 expression in three major RCC subtypes, and its association with clinical outcomes and adverse clinicopathologic features. A total of 101 nephrectomy samples at Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Thailand, from 2007 to 2017 were included in the study. XB130 immunohistochemistry was performed on slides from a tissue microarray comprised of 71 clear cell RCCs, 23 papillary RCCs, and 7 chromophobe RCCs, and were scored using a Histoscore system on a 0-300 scale. High XB130 expression in clear cell RCC and papillary RCC patients was associated with poor prognosis (log-rank test, P = 0.013, and P = 0.001, respectively). WHO/ISUP grade (P = 0.001) and XB130 high expression (P = 0.019) were found to be independent risk factors for mortality in clear cell RCC using multivariate analysis. The high expression of XB130 in clear cell RCC patients was also associated with high WHO/ISUP grade (P = 0.011), distant metastasis (P = 0.036), TNM stage (P = 0.007), sarcomatoid/rhabdoid differentiation (P = 0.061), and urinary collecting system invasion (P = 0.002). Similarly, high XB130 expression (P = 0.038) was associated with poor prognosis among papillary RCC patients as well as with lymphovascular invasion (P = 0.022), TNM stage (P = 0.030), and sarcomatoid/rhabdoid differentiation (P = 0.044). Overall, our findings showed that high XB130 expression in clear cell RCC and papillary RCC patients are associated with a worse prognosis. - Source: PubMed
Publication date: 2023/08/19
Ungarreevittaya PitiNintra OrapinSirithanaphol WichienChindaprasirt JarinSangkhamanon Sakkarn - Elucidating the mechanisms by which immune cells become dysfunctional in tumors is critical to developing next-generation immunotherapies. We profiled proteomes of cancer tissue as well as monocyte/macrophages, CD4 and CD8 T cells, and NK cells isolated from tumors, liver, and blood of 48 patients with hepatocellular carcinoma. We found that tumor macrophages induce the sphingosine-1-phospate-degrading enzyme SGPL1, which dampened their inflammatory phenotype and anti-tumor function . We further discovered that the signaling scaffold protein AFAP1L2, typically only found in activated NK cells, is also upregulated in chronically stimulated CD8 T cells in tumors. Ablation of in CD8 T cells increased their viability upon repeated stimulation and enhanced their anti-tumor activity synergistically with PD-L1 blockade in mouse models. Our data reveal new targets for immunotherapy and provide a resource on immune cell proteomes in liver cancer. - Source: PubMed
Publication date: 2023/05/30
Canale Fernando PNeumann Juliavon Renesse JanuszLoggi ElisabettaPecoraro MatteoVogel IanZoppi GiadaAntonini GaiaWolf TobiasJin WenjieZheng XiaoqinLa Barba GiulianoBirgin EmrullahForkel MarianneNilsson TobiasMarone RominaMueller HenrikPelletier NadegeJeker Lukas TCivenni GianlucaSchlapbach ChristophCatapano Carlo VSeifert LenaSeifert Adrian MGillessen SilkeDe Dosso SaraCristaudi AlessandraRahbari Nuh NErcolani GiorgioGeiger Roger